Low dose pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy

Journal of Urology

Volumn 156, Issue 5, 1996, Pages 1602-1605

  Hurle, R ^a   Losa, A ^a   Ranieri, A ^a   Graziotti, P ^a   Lembo, A ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

BCG vaccine; bladder neoplasms; carcinoma; immunotherapy; transitional cell

Indexed keywords

ANALGESIC AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; BCG VACCINE; ISONIAZID; MITOMYCIN C; SPASMOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CYSTITIS; EPIDIDYMITIS; FEMALE; FEVER; FOLLOW UP; HISTOLOGY; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

EID: 0029903416     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65458-2     Document Type: Article

References (28)

1. Boccon-Gibod, L., Leleu, C., Herve, J. M., Belas, M. and Steg, A.: Bladder tumors invading the lamina propia (stage A/T1): influence of endovesical bacillus Calmette-Guérin therapy on recurrence and progression. Eur. Urol., 16: 401, 1989.
2. Morales, A., Eidinger, D. and Bruce, A. W.: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 116: 180, 1976.
3. Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A., Sullivan, J., Sarosdy, M. F., Crissman, J. D. and Coltman, C. A.: A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitionalcell carcinoma of the bladder. New Engl. J. Med., 325: 1205, 1991.
4. Herr, H. W., Wartinger, D. D., Fair, W. R. and Oettgen, H. F.: BCG therapy for superficial bladder cancer: a 10-year followup. J. Urol., 147: 1020, 1992.
5. Martínez-Piñeiro, J. A., León, J. J., Martínez-Piñeiro, L., Jr., Fiter, L., Mosteiro, J. A., Navarro, J., Matres, M. J. G. and Cárcamo, P.: Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol., 143: 502, 1990.
6. Pagano, F., Bassi, P., Milani, C., Meneghini, A., Maruzzi, D. and Garbeglio, A.: A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol., 146: 32, 1991.
7. Bassi, P., Milani, C., Meneghini, A., Garbeglio, A., Zattoni, F., Piazza, N. and Pagano, F.: Dose response of bacillus Calmette-Guerin (BCG) in superficial bladder cancer: a phase III randomized trial low-dose vs standard-dose BCG regimen. J. Urol., part 2, 147: 273A, abstract 240, 1992.
8. Pagano, F., Bassi, P., Piazza, N., Abatangelo, G., Drago Ferrante, G. L. and Milani, C.: Improving the efficacy of BCG immunotherapy by dose reduction. Eur. Urol., suppl. 1, 27:19, 1995.
9. Martínez-Piñeiro, J. A., Solsona, E., Flores, N. and Isoma, S.: Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO. Eur. Urol., suppl. 1, 27: 13, 1995.
10. Morales, A., Nickel, J. C. and Wilson, J. W. L.: Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J. Urol., 147: 1256, 1992.
11. Lamm, D. L., Reichert, D. F., Harris, S. C. and Lucio, R. M.: Immunotherapy of murine transitional cell carcinoma. J. Urol., 128: 1104, 1982.
12. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. J. Amer. Stat. Ass., 53: 457, 1958.
13. Lee, E. T.: Statistical Methods for Survival Data Analysis. Belmont, California: Lifetime Learning Publications, pp. 19-26 and 109-112, 1980.
14. Cox, D. R.: Regression models and life tables. J. Roy. Stat. Soc., 34: 187, 1972.
15. Birch, B. R. P. and Harland, S. J.: The pT1 G3 bladder tumour. Brit. J. Urol., 64: 109, 1989.
16. Jakse, G., Loidl, W., Seeber, G. and Hofstadter, F.: Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J. Urol., 137: 39, 1987.
17. Siref, L. E. and Zincke, H.: Radical cystectomy for historical and pathologic T1, N0, M0 (stage A) transitional cell cancer. Urology, 31: 309, 1988.
18. Stökle, M., Alken, P., Engelman, U., Jacobi, G. H., Riedmiller, H. and Hohenfellner, R.: Radical cystectomy - often too late? Eur. Urol., 13: 361, 1987.
19. Herr, H. W., Laudone, V. P., Badalament, R. A., Oettgen, H. F., Sogani, P. C., Freedman, B. D., Melamed, M. R. and Whitmore, W. F., Jr.: BCG therapy alters the progression of superficial bladder cancer. J. Clin. Oncol., 6: 1450, 1988.
20. Herr, H. W.: Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guerin. J. Urol., 145: 40, 1991.
21. Eure, G. R., Cundiff, M. R. and Schellhammer, P. F.: Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer. J. Urol., 147: 376, 1992.
22. Hudson, M. A., Ratliff, T. L., Gillen, D. P., Haaff, E. O., Dresner, S. M. and Catalona, W. J.: Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J. Urol., 138: 295,1987.
23. Badalament, R. A., Herr, H. W., Wong, G. Y., Gnecco, C., Pinsky, C. M., Whitmore, W. F., Jr., Fair, W. R. and Oettgen, H. F.: A prospective randomized trial of maintenance versus non-maintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J. Clin. Oncol., 5: 441, 1987.
24. Lamm, D. L., Crawford, E. D., Blumenstein, B., Crissman, J. D., Montie, J., Gottesman, J., Lowe, B., Sarosdy, M. F., Bohl, R. D., Weems, W. L., Grossman, H. B., Smith, J. A., Beck, T. M., Leimert, J. and Coltman, C. A.: Maintenance BCG immunotherapy of superficial bladder cancer: a randomized prospective Southwest Oncology Group study. J. Urol., part 2, 147: 274A, abstract 242, 1992.
25. Cookson, M. S. and Sarosdy, M. F.: Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J. Urol., 148: 797, 1992.
26. Dal Bo, V., Belmonte, P., Veronesi, A., Lo Re, G., Miotto, E., Merlo, A., Volpe, R. and Francini, M.: Intravesical BCG instillations in patients with carcinoma in situ and pT1 G3 transitional cell carcinoma of the bladder. Eur. Urol., suppl. 1, 18: 43, abstract 82, 1990.
27. Pansadoro, V., Emiliozzi, P., Defidio, L., Donadio, D., Florio, A., Maurelli, S., Lauretti, S. and Sternberg, C. N.: Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J. Urol., 154: 2054, 1995.
28. Gilbert, H. A., Logan, J. L., Kagan, A. R., Friedman, H. A., Cove, J. K., Fox, M., Muldoon, T. M., Lonni, Y. W., Rowe, J. H., Cooper, J. F., Nussbaum, H., Chan, P., Rao, A. and Starr, A.: The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading. J. Urol., 119: 488, 1978.